CURRENT SELECTION

Human and dog CTA evidence

546 human CTA groups

582 loci / 18,031 Unsafe / 20 Neither

1,266 unassigned; dog selection remains unassessed

Sources, expression profiles, single-cutoff filtering and measured tissue evidence.

Safety and CTA identity

Assessment	Question	Current rule
Safety	Concerning healthy-tissue protein production?	Absolute RNA / IHC and clinical rules
Cancer expression	Expressed in a measured cancer?	One sample ≥2 TPM or pTPM
Adult restriction	Preferential to relevant adult normal expression?	Qualifying association signal > supported same-unit adult normal RNA
Reproductive / developmental	Affirmative expression in a qualifying context?	Reproductive ≥5 nTPM or supported developmental ≥5 TPM

Only safety can establish Unsafe. Other failed requirements block CTA. Missing evidence remains unknown.

Adult restriction and cancer presence

Assessment	Comparator
Cancer expression	One qualifying sample. No normal ratio.
Reproductive restriction	Qualifying reproductive nTPM > supported adult nTPM
Developmental restriction	Qualifying developmental TPM > supported adult TPM

Safety is absolute. Adult restriction is relative.

Compare supported Vital / Protected / Manageable expression. Exclude Reproductive / Disposable. Keep native units separate.

Published candidate lists

Paper	Groups	CTA	Unsafe	Neither	Unassigned
da Silva et al. (2017)	1,017	376	401	1	239
Wang et al. (2016)	988	264	640	1	83
Chang et al. (2019)	985	285	639	0	61
Gong et al. (2021)	729	337	306	0	86
Bruggeman et al. (2018)	692	23	663	0	6
Jamin et al. (2021)	469	34	427	0	8
Loriot et al. (2025)	202	81	101	0	20
Carter et al. (2023)	103	57	37	0	9
Hirbo et al. (2015)	78	12	64	0	2
Seager et al. (2024)	15	11	2	0	2
Sasaroli et al. (2011)	13	0	13	0	0
Garg et al. (2007)	5	3	2	0	0

Union: 2,514 groups / 2,570 loci. 438 selected groups have an annotation; 108 do not.

Broader published nominations


Paper	Published scope	Identity accounting
Sasaroli et al. (2011)	13 detailed tumor-vascular candidates	13 matched genes
Hirbo et al. (2015)	86 placenta-enriched genes, including 30 fast-evolving	82 matched, 4 unresolved
Compact source view	Bai, Boël and Bradley covered by larger sets	All memberships retained
Garg et al. (2007)	Still uniquely contributes SPAG9	Retained in main view

Vascular and placental nominations retain their scope. Paper membership never bypasses the quantitative funnel.

Overlap between published lists

Overlap between published lists

The six largest mapped paper sets; full pairwise tables are downloadable



Diagonal cells give each paper's set size. Off-diagonal cells count shared groups, not independent validation studies. Citations and original source-table IDs remain linked in the source inventory.

Reproductive and developmental association

Qualifying route	Entrants	Final CTA
Reproductive only	2,322	298
Developmental only	2,095	170
Both	10,910	78

Whole-reference RNA measurements create this set

The table counts association before adult restriction. Presence in a reproductive or developmental context does not establish restriction.

Normal and cancer measurement sources

Evidence	Source	Quantity
Normal / reproductive bulk	HPA consensus + HPA brain + direct GTEx	nTPM / TPM
Normal tissue cells	HPA clusters, at least 20 reads	nTPM
Immune cells	HPA / Monaco / original DICE	Native nTPM / TPM
Adult cornea	Collin et al., GSE155683	CP10K
Normal protein	HPA + curated external IHC	Staining / reagent confidence
Cancer	132 compatible OncoRef cohort views + HPA	TPM / protein-coding TPM
Developmental	Tyser gastrulation + Petropoulos preimplantation	Stage / lineage mean TPM

DICE and corneal coverage are optional. Measured counterevidence still contributes.

CURRENT POLICY

RNA cutoffs

Ceiling	Missing / unusable	Approved –	Supported –	Enhanced –
Vital	4	8	16	32
Protected	8	16	32	64
Manageable	16	32	64	128

One boundary: above-cutoff Vital / Protected is Unsafe


Manageable excess blocks CTA. Bowel epithelium and identified fibroblasts use Manageable. Equality passes.

Neither requires a measured expression profile

Profile	Required evidence	Groups
Low expression	RNA below 2 across measured normal / reproductive / embryonic / tumor panels; no detected protein	9
Diffuse Manageable	No association route; RNA ≥2 in at least two Manageable tissue concepts; no Vital / Protected exclusion	11

Both require complete normal RNA coverage and resolved evidence. Other failures remain unassigned.

Every filtering layer can contribute



Final: 546 CTA / 18,031 Unsafe / 20 Neither / 1,266 unassigned.

Removals at each filter

Layer	First removals	Eligible	Unsafe
Association	4,536	15,327	0
Tumor sample ≥2 TPM/pTPM	13	15,314	0
Adult restriction	10,212	5,102	0
HPA normal protein	3,041	2,061	10,094
Required RNA coverage	71	1,990	10,094
Normal bulk	1,284	706	17,500
HPA tissue clusters	130	576	17,914
HPA immune	7	569	17,944
Monaco immune	3	566	17,961
DICE immune	15	551	18,016
Adult cornea	3	548	18,028
Accepted normal-protein evidence	1	547	18,030
Clinical safety exclusion	1	546	18,031
External validated normal protein	0	546	18,031
Neither expression profiles	0	546	18,031


Every group remains available to every later evidence layer.

IHC matching to measured RNA compartments

Context	Evidence and current ceiling
PRAME colon epithelial cells	20.3 nTPM / 96 reads; Enhanced-negative glandular IHC; Manageable 128
PRAME adrenal bulk	3.6 nTPM; incomplete compartment IHC coverage; Vital 4
CTAG2 bronchial basal cells	24.9 nTPM / 58 reads; Enhanced-negative respiratory IHC; Vital 32
Unrelated cells in the same tissue	No negative-IHC credit without exact or declared compartment coverage


PRAME and CTAG2 pass this policy. Parent-compartment sensitivity and PRAME's Low adrenal protein remain explicit limitations.

Selected CTA: reproductive versus embryonic RNA




Gray: healthy measurement unavailable. The lower band has no embryonic-expression value.

Selected CTA: healthy RNA in TPM




Gray: healthy measurement unavailable. The lower band has no embryonic-expression value.

Selected CTA: normal corneal RNA




Gray: healthy measurement unavailable. The lower band has no embryonic-expression value.


High reproductive and embryonic RNA: labels 1 of 3



High reproductive and embryonic RNA: labels 2 of 3



High reproductive and embryonic RNA: labels 3 of 3




Complementary embryonic measurements

Source	Measured cells / embryos	Developmental scope
Tyser et al. (2021)	1,195 cells / 1 embryo	Gastrulation, Carnegie stage 7
Petropoulos et al. (2016)	1,519 cells / 88 embryos	Preimplantation, days 3–7
Recovered coverage	683 of 1,006 earlier missing groups	Measured TPM, including familiar CTAs


PRAME, MAGE-A4, CTAG1A/B, XAGE1A/B and CT83 now have TPM rows

Each source keeps its own stages. Neither atlas covers all fetal or pediatric development.

Widely studied antigens: reproductive RNA



Widely studied antigens: embryonic RNA



Assessment status is separate from category

API status	Meaning	Human groups
screened	CTA, Unsafe or Neither assigned	18,597
incomplete_evidence	Unassigned with missing coverage or unresolved evidence	617
outside_category_definitions	Tracked coverage checks pass; no definition fits	649
unassessed	No species-specific selection policy applied	0

Neither requires a measured biological profile. Unassigned does not mean Unsafe or low expression.

Which sources have incomplete evidence

Source or unresolved evidence	Groups
HPA v23 consensus bulk	414
Combined normal bulk: HPA consensus + HPA brain + direct GTEx	366
HPA v23 tissue-cell clusters	335
HPA v23 immune cells	304
Monaco immune cells via HPA v23	304
Combined Tyser + Petropoulos TPM	296
No tumor measurement: OncoRef + HPA	34
Measured tumor, incomplete group profile	17
HPA v23 Uncertain normal-tissue IHC	28

Overlapping gaps within 617 unassigned groups. DICE and corneal coverage are optional.

Dog evidence and integration gaps

Layer	Available evidence / remaining gap
Nominations	5 + 10 – 1 shared = 14 native nominations
Identity	13 unique mappings; one ambiguous MAGE-family assay
Normal / developmental RNA	Bgee TPM and BarkBase TMM-CPM need reference reconciliation
Tumor RNA	GSE304066 count/FPKM and reference conflicts remain unresolved
Normal protein	Limited study IHC; Pfizer pooled iBAQ is not cell-resolved IHC
Selection	All 14 unassigned / unassessed; no canine quantitative policy

Human thresholds, antibody grades and normal-tissue absence never transfer by orthology.

Curated oncofetal sources

Source	Scope and integration status
Tyser + Petropoulos	Current gastrulation and preimplantation TPM sources
Shaw et al. (2024)	157 cancer-specific targets; six oncofetal annotations. Exon-specific scope retained
TRIM71 liver study (2024)	Liver oncofetal signature; requires identity and measurement ingestion
Cardoso-Moreira et al. (2019)	Developmental organ trajectories with child/adult comparisons; not integrated

Published nominations need independent normal/tumor filtering and postnatal coverage.

Common API with native evidence underneath

```
results = cta_selection.results(species="human")
audit = cta_selection.audit(species="human")
audit.sources    audit.overlaps    audit.funnel
audit.explain("PRAME")
```

Field	Meaning
category	CTA / Unsafe / Neither, or null when unassigned
assessment_status	Screened, incomplete evidence, outside definitions, or unassessed
gene_ids / gene_identities	All group members, stable IDs, history and curated synonyms

Source-specific native units, tissue/cell context, confidence and coverage remain inspectable.

Every source resolves to a concrete version

```
catalog.ensure("gtex_tissue_rna")              # v11
catalog.ensure("gtex_tissue_rna", version="v10")
catalog.provenance("gtex_tissue_rna", "v11")
```

Shared choice	Source-specific meaning
Default / latest	Newest registered release; saved runs keep explicit pins
Concrete version	GTEx v11; HPA v25.1; a study snapshot or OncoRef build
Provenance	Version, content checksum, native unit, annotation and pipeline
Species	The same selector applies to native dog and mouse assets

This analysis pins GTEx v11 and HPA v23 normal panels. A newer public default does not rewrite it.